Danaher (DHR)
(Delayed Data from NYSE)
$239.25 USD
-0.75 (-0.31%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $239.25 0.00 (0.00%) 7:58 PM ET
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
DHR 239.25 -0.75(-0.31%)
Will DHR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DHR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DHR
The Zacks Analyst Blog Highlights Walmart, Exxon Mobil, Danaher and GSI Technology
Top Stock Reports for Walmart, Exxon Mobil & Danaher
DHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Hold Strategy Is Apt for Danaher (DHR) Stock Now
Why Is Danaher (DHR) Up 6.7% Since Last Earnings Report?
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants
Other News for DHR
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Barclays Sticks to Its Hold Rating for Danaher (DHR)
Cepheid Receives FDA Authorization with CLIA Waiver for Xpert® HCV
August 9th Options Now Available For Danaher (DHR)
Agilent Hit By Cyclical Headwinds, But The Growth Story Remains Intact Long Term